Novartis
Novartis to highlight Gilenya data at neurology congress
April 13, 2015Sales and Marketing American Academy of Neurology, Novartis, fingolimod, gilenya
Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …
Drug development showcasing at AACR conference
April 13, 2015Research and Development, Sales and Marketing American Association of Cancer Research, AstraZeneca, Bayer, Genentech, Novartis, aacr
This month’s American Association of Cancer Research conference is set to showcase the latest studies in oncology. Roche’s biotech subsidiary …
Hundreds of jobs threatened after big pharma deals close
April 7, 2015Medical Communications, Research and Development, Sales and Marketing Deals, GSK, Jobs, Novartis, US, Valeant, job losses, redundancy, salix
Fresh from deals worth a combined $34 billion, GSK and Salix Pharmaceuticals have announced company restructures that have placed more …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
Novartis drug to treat iron overload gets US nod
March 31, 2015Sales and Marketing FDA, Novartis, blood, deferasirox, exjade, iron, jadenu
Novartis’ iron overload drug Jadenu has been given the green light by US regulators to treat patients with a serious …
Novartis in major oncology drive
March 30, 2015Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia
Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …
GSK and UK government agree meningitis B vaccine deal
March 30, 2015Sales and Marketing AstraZeneca, Bexsero, GSK, Novartis, meningitis v, vaccines
The UK government has agreed a deal with GlaxoSmithKline to provide its meningitis B vaccine Bexsero on the NHS, after …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
GSK sells off stake in Aspen for $853m
March 13, 2015Sales and Marketing Africa, China, GSK, Novartis, Singapore, aspen, merger, redfern
GlaxoSmithKline has sold off half its stake in South Africa’s Aspen Pharmacare in a move that will net the British …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
NICE approves Roche’s Gazyvaro and Novartis’ Xolair
March 11, 2015Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab
NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …
Novartis secures first US biosimilar product
March 6, 2015Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz
Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …
Three drugs put forward for EMA authorisation
March 2, 2015Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia
Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …
GSK and Novartis swap assets
March 1, 2015Research and Development, Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, akt, merger, oncology, vaccines
GlaxoSmithKline’s planned major assets swap with Novartis has completed today as was predicted last week. Both firms announced the overhaul …
Latest content
FibroFind appoints Lee Borthwick as CEO
